Given the wide range of different business models in the DTx industry, an important question emerges: which are the most successful business models and routes to market for DTx thus far? For instance, products for Irritable Bowel Syndrome could easily be D2C and gain traction faster through pay out of pocket rather than a DTx product for depression that needs to be prescribed by a clinician. So, is there a right or easy business model in DTx? In this meeting we will delve into the understanding of the different business models and how they determine the success of a DTx product.